Variant of Uncertain Significance: What It Means and How to Guide Your Patients

Genetic testing has become a routine part of clinical care — but when results come back with a “Variant of Uncertain Significance,” the conversation between clinician and patient often breaks down. Patients panic. Some demand action. Others disengage entirely.

The challenge isn’t just scientific. It’s communicative. VUS results are among the most common findings in hereditary cancer testing and diagnostic genomics, yet they remain widely misunderstood by patients — and inconsistently explained by the clinical teams delivering them.

This article breaks down what a VUS actually means, why labs issue them, and how healthcare professionals can guide patients toward the right response — without over- or under-reacting to a fundamentally uncertain result.

What Is a Variant of Uncertain Significance?

The human genome contains roughly 3 billion base pairs. A “variant” is any difference in a patient’s DNA sequence compared to a reference genome — and every person carries thousands of them, the vast majority clinically irrelevant.

When a clinical laboratory analyzes sequencing results, each variant is classified using a standardized five-tier system developed by the American College of Medical Genetics and Genomics (ACMG):

Classification	What It Means
Pathogenic	The variant is known to cause disease
Likely Pathogenic	Strong evidence it causes disease
Variant of Uncertain Significance (VUS)	Not enough evidence to classify it either way
Likely Benign	Strong evidence it does NOT cause disease
Benign	Known to be harmless

A VUS sits squarely in the middle. It’s not confirmed harmful. It’s not confirmed harmless. Science simply hasn’t accumulated enough data on this specific variant yet to make a clear call.

The critical clinical point: a VUS is not a diagnosis, and should not be treated as one.

Why Do VUS Results Happen?

A VUS result is not a lab error. It’s an honest reflection of where genomics science currently stands — and understanding the drivers helps clinicians frame the result accurately for patients.

Scale of the genome. The sheer volume of variants surfaced by next-generation sequencing analysis means that rare, previously unseen variants are a routine output — not an anomaly. Many simply haven’t appeared in enough patient cohorts to build a sufficient evidence base for classification.

Database representation gaps. Most population-level genomic databases have historically skewed toward patients of European ancestry. Variants from underrepresented populations are statistically more likely to return as VUS — not because they carry greater clinical risk, but because comparative reference data is thinner. This is an active and improving area across the field.

The science moves fast. A variant classified as uncertain today may have a definitive answer within months or years as new functional studies are published, population databases expand, and more patients contribute data to research registries.

How Do Labs Actually Classify Variants?

Variant classification is a structured, evidence-based process — not guesswork. Clinical labs evaluate multiple evidence streams for each variant: population frequency data, functional impact on the gene, segregation with disease in family studies, and prior reports in scientific literature.

To apply this multi-factor assessment consistently at scale, clinical laboratories rely on clinical genomics software that systematically scores each piece of evidence according to ACMG criteria. Automating this process reduces inter-analyst variability and ensures that classification decisions are reproducible, auditable, and compliant with evolving guidelines.

The result lands in one of those five ACMG tiers. When the cumulative evidence doesn’t meet the threshold for Likely Pathogenic or Likely Benign in either direction, the result is a VUS — a transparent acknowledgment of the current limits of available data.

Can a VUS Change Over Time?

Yes — and reclassification is one of the most clinically significant dynamics in hereditary genomics.

As more patients are sequenced, functional studies accumulate, and databases like ClinVar expand, labs regularly revisit VUS classifications. A variant that is uncertain today can be:

• Upgraded to Likely Pathogenic or Pathogenic as new evidence confirms disease association
• Downgraded to Likely Benign or Benign as population data shows the variant is common and benign

Many labs maintain active reclassification programs and notify ordering clinicians or patients when a variant’s status changes — sometimes months or years after the original report. Clinicians should set patient expectations around this upfront: a reclassification letter isn’t alarming news, it’s the system functioning as designed.

Guiding Patients After a VUS Result

The clinical challenge isn’t just interpreting the variant — it’s managing the patient response. Here’s a practical framework for the post-result conversation:

1. Anchor on what it isn’t

A VUS alone almost never changes immediate clinical management. Patients should understand that no surgery, prophylactic treatment, or major lifestyle change is warranted based on a VUS result in isolation. Frame the uncertainty as bilateral — it’s neither a green light nor a red flag.

2. Refer to genetic counseling

Genetic counselors are the most effective resource for translating VUS results into patient-appropriate context, factoring in personal and family history, the specific gene involved, and whether surveillance or follow-up is appropriate. If genetic counseling wasn’t part of the initial testing pathway, a referral at this stage is strongly advisable.

3. Extend the conversation to family members

Even without a clear clinical interpretation, first-degree relatives may benefit from knowing that a VUS exists in the family — particularly if the variant is ever reclassified. Proactive communication now reduces the logistical burden of cascade testing later.

4. Clarify reclassification procedures

Patients should know whether the ordering lab has a proactive reclassification notification policy. If not, setting a periodic follow-up cadence — particularly for variants in high-penetrance genes — is a reasonable clinical practice.

5. Direct patients toward research participation

Several registries and research programs specifically recruit patients carrying VUS results. Participation can directly accelerate reclassification for the patient’s variant and contribute to population-level genomic data equity.

VUS vs. Pathogenic: Key Differences at a Glance

	VUS	Pathogenic
What it means	Unclear significance	Known to cause disease
Immediate action required?	Rarely	Often yes
Changes clinical management?	Usually not	Usually yes
Can it be reclassified?	Yes, frequently	Rarely
Should family members be told?	Possibly	Yes
Should you see a genetic counselor?	Yes	Yes

The Bottom Line

A Variant of Uncertain Significance is exactly what the classification says: uncertain. It is not a diagnosis, and it should not drive clinical action in isolation. It is a transparent acknowledgment that current evidence is insufficient to call the variant harmful or harmless — and that answer may well come with time.

The genomics field is evolving faster than almost any other area of medicine. Databases are expanding, sequencing costs continue to fall, and the computational infrastructure clinical labs use to interpret variants is growing more sophisticated every year. The VUS that has no clear answer today is far more likely to be resolved in the near future than it would have been five years ago.

For healthcare professionals, the task is helping patients hold that uncertainty without either dismissing it or catastrophizing it — and making sure the systems are in place to catch a reclassification when it arrives.